Abstract:BACKGROUND AND AIMS:Fatty acid translocase CD36 (CD36) is a membrane protein with multiple immuno-metabolic functions. Palmitoylation has been suggested to regulate the distribution and functions of CD36, but little is known about its significance in non-alcoholic steatohepatitis (NASH). METHODS:Human liver tissue samples were obtained from patients undergoing liver biopsy for diagnostic purposes. CD36 knockout mice were injected with lentiviral vectors expressing wild-type CD36 or CD36 with mutated palmitoylation sites. Liver histology, immunofluorescence, mRNA expression profile, subcellular distributions and functions of CD36 protein were assessed. RESULTS:The localization of CD36 on the plasma membrane of hepatocytes was markedly increased in patients with NASH compared to patients with normal liver and those with simple steatosis. Increased CD36 palmitoylation and increased localization of CD36 on the plasma membrane of hepatocytes were also observed in livers of mice with NASH. Furthermore, inhibition of CD36 palmitoylation protected mice from developing NASH. The absence of palmitoylation decreased CD36 protein hydrophobicity reducing its localization on the plasma membrane as well as in lipid raft of hepatocytes. Consequently, a lack of palmitoylation decreased fatty acid uptake and CD36/Fyn/Lyn complex in HepG2 cells. Inhibition of CD36 palmitoylation not only ameliorated intracellular lipid accumulation via activation of the AMPK pathway, but also inhibited the inflammatory response through the inhibition of the JNK signaling pathway. CONCLUSIONS:Our findings demonstrate the key role of palmitoylation in regulating CD36 distributions and its functions in NASH. Inhibition of CD36 palmitoylation may represent an effective therapeutic strategy in patients with NASH. LAY SUMMARY:Fatty acid translocase CD36 (CD36) is a multifunctional membrane protein which contributes to the development of liver steatosis. In the present study, we demonstrated that the localization of CD36 on the plasma membrane of hepatocytes is increased in patients with non-alcoholic steatohepatitis. Blocking the palmitoylation of CD36 reduces CD36 distribution in hepatocyte plasma membranes and protects mice from non-alcoholic steatohepatitis. The inhibition of CD36 palmitoylation not only improved fatty acid metabolic disorders but also reduced the inflammatory response in vitro and in vivo. The present study suggests that CD36 palmitoylation is important for non-alcoholic steatohepatitis development and inhibition of CD36 palmitoylation could be used to cure non-alcoholic steatohepatitis.

Secretory Galectin-3 promotes hepatic steatosis via regulation of the PPARγ/CD36 signaling pathway

Galectin-3 Ablation Enhances Liver Steatosis, but Attenuates Inflammation and IL-33-Dependent Fibrosis in Obesogenic Mouse Model of Nonalcoholic Steatohepatitis

Chronic high-fat diet induces galectin-3 and TLR4 to activate NLRP3 inflammasome in NASH

Association between galectin-3 and hepatosteatosis in a community-based cross-sectional study

Galectin-3 Impairs Calcium Transients and Β-Cell Function

Galectin-3 regulates inflammasome activation in cholestatic liver injury.

Inhibition of galectin-3 ameliorates the consequences of cardiac lipotoxicity in a rat model of diet-induced obesity

Exogenous galanin alleviates hepatic steatosis by promoting autophagy via the AMPK-mTOR pathway

Functional Proteomic Analysis of Nonalcoholic Fatty Liver Disease in Rat Models: Enoyl-coenzyme a Hydratase Down-Regulation Exacerbates Hepatic Steatosis

GCSF Deficiency Attenuates Nonalcoholic Fatty Liver Disease Through Regulating GCSFR-SOCS3-JAK-STAT3 Pathway and Immune Cells Infiltration.

Fatty Acids Promote Fatty Liver Disease Via the Dysregulation of 3-Mercaptopyruvate Sulfurtransferase/hydrogen Sulfide Pathway.

Hepatocyte-secreted FAM3D Ameliorates Hepatic Steatosis by Activating FPR1-hnRNP U-GR-SCAD Pathway to Enhance Lipid Oxidation

Galectin‐3 Exacerbates Ox‐ldl‐mediated Endothelial Injury by Inducing Inflammation Via Integrin Β1‐rhoa‐jnk Signaling Activation

Galectin-12 modulates Kupffer cell polarization to alter the progression of nonalcoholic fatty liver disease

CD36 palmitoylation disrupts free fatty acid metabolism and promotes tissue inflammation in non-alcoholic steatohepatitis.

SUMO-specific protease 3 is a key regulator for hepatic lipid metabolism in non-alcoholic fatty liver disease

Galectin 3‐binding protein (LGALS3BP) depletion attenuates hepatic fibrosis by reducing transforming growth factor‐β1 (TGF‐β1) availability and inhibits hepatocarcinogenesis

Galanin Receptor 2 Mediates Antifibrogenic Effects of Galanin on Hepatic Stellate Cells

Hepatic IL22RA1 deficiency promotes hepatic steatosis by modulating oxysterol in the liver

The Effect of Seal Oil on Galectin-3 in Serum and Livers of Rats with Nonalcoholic Steatohepatitis

Hepatic Clstn3 Ameliorates Lipid Metabolism Disorders in High Fat Diet-Induced NAFLD through Activation of FXR